Search
for

    GlossaryGlibenclamide

    oral diabetes medication that stimulates insulin release from the pancreas

    Glibenclamide, also known as Glyburide, is an oral medication used to manage type 2 diabetes. It belongs to a class of drugs called sulfonylureas, which work by stimulating the pancreas to release more insulin, thereby helping to lower blood sugar levels.

    Related Terms

    Learn

    5 / 801 results

    Research

    5 / 121 results

    Community Join

    5 / 1000+ results

      community Anagenic is trying to compound Gt20029

      in Treatment  56 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

      community Pyrludimide (KX-826) or Breezula (clascoterone)

      in Treatment  9 upvotes 3 months ago
      The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

      community EMA is re-examining Winlevi (clascoterone at lower concentration)

      in Treatment  8 upvotes 1 year ago
      Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

      community So Pyrilutamide has been postponed by one year. How likely is that to happen to GT20029

      in Treatment  27 upvotes 2 years ago
      The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.